Meridian Bioscience (VIVO) Stock Price, News & Analysis

Company Overview

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Key Stats

• Today's Range: $33.97 to $33.97
• 50-Day Range: $33.00 to $33.97
• 52-Week Range: $20.35 to $34.38
• Volume: N/A
• Average Volume: 973,737 shs
• Market Capitalization: $1.50 billion
• P/E Ratio: 35.02
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Meridian Bioscience Stock Analysis - MarketRank™

Meridian Bioscience scored higher than 21% of companies evaluated by MarketBeat, and ranked 873rd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Meridian Bioscience.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Meridian Bioscience is 35.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.15.

Price to Earnings Ratio vs. Sector

The P/E ratio of Meridian Bioscience is 35.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 94.60.

Price to Book Value per Share Ratio

Meridian Bioscience has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for VIVO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Meridian Bioscience does not currently pay a dividend.

Dividend Growth

Meridian Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.88

Short Interest

There is no current short interest data available for VIVO.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

6 people have searched for VIVO on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Meridian Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.30% of the stock of Meridian Bioscience is held by insiders.

Percentage Held by Institutions

89.72% of the stock of Meridian Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VIVO Stock Analysis - Frequently Asked Questions

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) issued its earnings results on Friday, November, 12th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.21 by $0.03. The business earned $76.20 million during the quarter, compared to analyst estimates of $68.40 million. Meridian Bioscience had a trailing twelve-month return on equity of 16.74% and a net margin of 12.70%.

Does Meridian Bioscience have any subsidiaries?

Meridian Bioscience subsidiaries include Exalenz Bioscience.

What other stocks do shareholders of Meridian Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Meridian Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Micron Technology (MU) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 11/21/2024
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:VIVO
• CUSIP: 58958410
• CIK: 794172
• Web: www.meridianbioscience.com
• Phone: (513) 271-3700
• Fax: 513-271-3762
• Employees: 702
• Year Founded: 1977

Profitability

• EPS (Most Recent Fiscal Year): $0.97
• Trailing P/E Ratio: 35.02
• Forward P/E Ratio: 40.93
• P/E Growth: N/A
• Net Income: $42.46 million
• Net Margins: 12.70%
• Pretax Margin: 16.31%
• Return on Equity: 16.74%
• Return on Assets: 13.09%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 3.63
• Quick Ratio: 2.46

Sales & Book Value

• Annual Sales: $333.02 million
• Price / Sales: 4.49
• Cash Flow: $1.78 per share
• Price / Cash Flow: 19.13
• Book Value: $8.41 per share
• Price / Book: 4.04

Miscellaneous

• Outstanding Shares: 44,010,000
• Free Float: 42,996,000
• Market Cap: $1.50 billion
• Optionable: Optionable
• Beta: 0.23